BELLEVILLE, ON, Dec. 4 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC), a
research-based, technology-driven Canadian biopharmaceutical company, today
announced that it has been recognized as one of Canada's Top 10 Life Sciences
Companies for 2008. Bioniche was chosen by a group of distinguished venture
capital investors based on the Company's attractiveness as an exceptional
investment in Canada.
"We are honoured to have received this award," said Mr. Graeme McRae,
President & CEO of Bioniche Life Sciences Inc. "It recognizes the significant
achievements made by our company in the last year, including the initiation of
our Phase III clinical trial with our proprietary Mycobacterial Cell Wall-DNA
Complex (MCC) in human bladder cancer and the authorization of our E. coli
O157:H7 food safety cattle vaccine for Canadian distribution, followed by
preliminary sales of this important food safety product."
Winners of the Top 10 Competition are chosen by an independent expert
panel of Canadian and U.S. venture capitalists. Originally developed to
promote the 10 most promising life science companies from across Canada to
Canadian and international investors and partners, the competition has now
expanded to showcase Canada's cleantech and technology sectors. Winning
companies, working in partnership with Canadian Consulates in Boston, New York
City, San Diego and San Francisco, participate in targeted investment forums
in each city, providing them with an opportunity to meet with venture capital
investors who have expressed an active interest in financing these companies.
In March of this year, Bioniche was recognized with a Genesis Award from
the Québec biotechnology, health technology and life science industry. The
"Transfer-Emergence" award was presented to the Company as part of the
BIOMEDEX 2007 convention-exhibition.
In September, the Company's E. coli O157:H7 cattle vaccine was recognized
internationally as the best new veterinary product for livestock as part of
the Animal Pharm Industry Excellence Awards '07. The "best new veterinary
product for livestock" award recognizes excellence in pharmaceutical or
vaccine development for production animals. In this category, the 12-member
panel of independent industry judges looked for the product that represented
the greatest therapeutic, prophylactic, or production advance.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery, development,
manufacturing, and marketing of proprietary products for human and animal
health markets worldwide. The fully-integrated company employs approximately
195 skilled personnel and has three operating divisions: Human Health, Animal
Health, and Food Safety. The Company's primary goal is to develop proprietary
cancer therapies supported by revenues from marketed products in human and
animal health. For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.
For further information:
For further information: Jennifer Shea, Corporate Communications &
Investor Relations Manager, Bioniche Life Sciences Inc., Telephone: (613)
966-8058 ext. 1250, Cell: (613) 391-2097, Jennifer.Shea@Bioniche.com